Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO

Daiichi Sankyo (TSE: 4568) will present data at ASCO 2025, highlighting potential new standards of care for cancer patients. Key data includes results from the DESTINY-Breast09 phase 3 trial, showing ENHERTU, in combination with pertuzumab, demonstrating superior progression-free survival compared to taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer and from the DESTINY-Gastric04 phase 3 trial where ENHERTU demonstrated superior overall survival compared to ramucirumab and paclitaxel as a second-line treatment in patients with HER2 positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The presentations underscore Daiichi Sankyo's commitment to advancing oncology treatments and its DXd ADC portfolio.

Analysis

Daiichi Sankyo (TSE: 4568) is poised to present highly significant clinical data at the 2025 American Society of Clinical Oncology (ASCO) Scientific Program, with over 20 abstracts accepted, prominently featuring its flagship antibody-drug conjugate (ADC), ENHERTU. Two late-breaking oral presentations are particularly noteworthy: the DESTINY-Breast09 phase 3 trial demonstrated ENHERTU combined with pertuzumab achieved superior progression-free survival over the standard taxane, trastuzumab, and pertuzumab (THP) regimen in first-line HER2 positive metastatic breast cancer. Concurrently, the DESTINY-Gastric04 phase 3 trial showed ENHERTU provided superior overall survival compared to ramucirumab and paclitaxel in second-line HER2 positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. These results, which will be featured in ASCO press briefings, suggest ENHERTU could redefine standard of care in these settings, marking the fourth consecutive year of potential practice-changing ENHERTU data at ASCO and bringing its total to six breast and two gastric cancer randomized trials showing significant survival improvements. Further ENHERTU data includes an exploratory analysis of DESTINY-Breast06 in HER2-low/ultralow metastatic breast cancer. Beyond ENHERTU, Daiichi Sankyo will showcase advancements with DATROWAY (datopotamab deruxtecan) in non-small cell lung cancer (NSCLC), including updated combination data from TROPION-Lung02 and first data from TROPION-Lung04, alongside patritumab deruxtecan (HER3-DXd) results from HERTHENA-Lung02 in EGFR-mutated NSCLC. The breadth of data underscores the strength of Daiichi Sankyo's DXd ADC portfolio, developed in part through collaborations with AstraZeneca and Merck & Co., Inc., and reflects a strong positive sentiment (overall 0.85, for Daiichi Sankyo 0.9) with high anticipated market impact.

Key Decisions for Investors

• Investors should closely monitor Daiichi Sankyo's ASCO presentations, particularly the late-breaking ENHERTU data from DESTINY-Breast09 and DESTINY-Gastric04, as positive outcomes could significantly expand ENHERTU's market and reinforce its blockbuster potential.
• Consider the implications of these trial results for Daiichi Sankyo's revenue trajectory and competitive positioning in the oncology market, as establishing new standards of care can lead to substantial market share gains.
• Evaluate the progress of the broader DXd ADC pipeline, including DATROWAY and patritumab deruxtecan, as continued positive data across multiple assets could de-risk the portfolio and enhance long-term growth prospects.
• Note the upcoming investor conference call scheduled for June 2/3, 2025, which will provide further management insights into the ASCO data and strategic outlook.